Skip to main content
ALDX
NASDAQ Life Sciences

Aldeyra Q3: Cash Down to $41M, Loss Narrows, FDA Appeal Pending

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.616
Mkt Cap
$37.155M
52W Low
$0.527
52W High
$5.93
52W Position info
17% above low
Off High info
90% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ALDX sits 17% above its 52-week low of $0.527.

Summary

Aldeyra ended Q3 2026 with $41.0M in cash, enough to fund operations into 2029, while it appeals the FDA's reproxalap rejection and carries a narrowed $12.7M nine-month loss.


Key Events · Earnings and Guidance · ALDX

  • Cash Falls to $41.0M

    Cash and cash equivalents were $40,974,979 at September 30, 2026, down from $70,041,254 at December 31, 2025, after the $15.0M Hercules loan repayment.

  • Loss Narrows on R&D Cuts

    Nine-month net loss was $12.7M versus $27.4M a year earlier; R&D fell 63.8% to $7.7M as focus shifted from clinical to regulatory work.

  • Runway Into 2029

    Management states cash is sufficient to fund projected operating expenses into 2029, including the FDRR process.

  • FDA Appeal Filed

    An FDRR appealing the 2026 Complete Response Letter for reproxalap was submitted October 26, 2026, with an OND meeting expected in Q4 2026.


Analysis · ALDX · Life Sciences

The quarter's headline is the shrinking cash pile: $41.0M at September 30 versus $70.0M at year-end, after repaying the $15.0M Hercules loan in April. Management says that cash funds operations into 2029, which buys time while the company appeals the FDA's March 2026 Complete Response Letter for reproxalap through a Formal Dispute Resolution Request filed October 26, 2026. The loss narrowed sharply ($12.7M for nine months vs $27.4M) mostly because R&D spending fell 63.8% as the company shifted from clinical work to regulatory activity. The AbbVie option remains unexercised as of November 5, 2026, so the $100M upfront and up to $300M in milestones are still contingent on an FDA approval that has not happened. A securities class action over prior reproxalap disclosures was amended October 9, 2026, adding legal overhang.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALDX was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.2M. The 52-week trading range was $0.53 to $5.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALDX - Latest Insights

ALDX
Nov 17, 2026, 4:50 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6939
Real-time Price: $0.7217 info
Change: +$0.0278 (+4%) info
Market Cap: $43.559M info
ALDX
Nov 09, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.636
Real-time Price: $0.7217 info
Change: +$0.0857 (+13%) info
Market Cap: $43.559M info
ALDX
Sep 29, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.7217 info
Change: -$0.4771 (-40%) info
Market Cap: $43.559M info
ALDX
Jul 15, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.7217 info
Change: -$1.20 (-62%) info
Market Cap: $43.559M info
ALDX
Jun 09, 2026, 8:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $0.7217 info
Change: -$0.9983 (-58%) info
Market Cap: $43.559M info